Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2012

View Archived Issues

Imipramine blue with doxorubicin improves survival in glioma model

Positive phase I results presented for Achillion's NS5A inhibitor

Janssen Pharmaceutica designs new series of compounds for pain

Scientists at Antoxis disclose novel antioxidant compounds

XMetA improves experimental hyperglycemia

hMaxi-K gene transfer appears safe in women with overactive bladder

Follow-up of AAV2-FIX study patients shows low risk of insertional mutagenesis

Spanish team discloses new treatments for Huntington's disease

Canadian researchers present new vaccines for influenza

Influenza vaccine triggers protective HAI titers against unmatched H5N1 strains

New treatments for obesity described by Takeda Pharmaceutical

Novel isoflavones discovered at Nanjing University of Technology

Hisamitsu Pharmaceutical seeks approval for transdermal oxybutynin in Japan

Adamas ready to begin phase III studies of memantine/donepezil capsules

Trimel Pharmaceuticals begins enrollment in phase II Tefina trial

PCI Biotech enrolls first patient in phase II ENHANCE study of Amphinex

NovaBay enrolls first patients in phase IIb BAYnovation study

FDA accepts amendment to Northwest's DCVax-L trial in brain cancer

Ambit Biosciences and Teva receive IND clearance for CEP-32496

Spectrum Pharmaceuticals begins Zevalin/motexafin combination study

Urocortin 2 improves cardiac output in acute decompensated heart failure

New phase II trial investigates ladostigil in mild cognitive impairment

Vertex and CCFC fund Canadian research in IBD

Levotofisopam proof-of-concept trial successfully completed

FDA approves new administration schedule for BioThrax

Epodure to begin first U.S. trial for treatment of anemia in dialysis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...